45 related articles for article (PubMed ID: 38468341)
1. Role of Surgery in Combination with Immunotherapy.
Klemen ND; Shindorf ML; Sherry RM
Surg Oncol Clin N Am; 2019 Jul; 28(3):481-487. PubMed ID: 31079801
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
3. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
Wong P; Wisneski AD; Tsai KK; Chang TT; Hirose K; Nakakura EK; Daud AI; Maker AV; Corvera CU
World J Surg Oncol; 2024 Mar; 22(1):77. PubMed ID: 38468341
[TBL] [Abstract][Full Text] [Related]
4. Use of immunotherapy and surgery for stage IV melanoma.
Molina G; Kasumova GG; Qadan M; Boland GM
Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
[TBL] [Abstract][Full Text] [Related]
5. Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy.
Medina BD; Choi BH; Rodogiannis KG; Moran U; Shapiro RL; Pavlick A; Osman I; Berman RS; Lee AY
J Surg Oncol; 2020 Sep; 122(3):555-561. PubMed ID: 32441371
[TBL] [Abstract][Full Text] [Related]
6. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.
Klemen ND; Feingold PL; Goff SL; Hughes MS; Kammula US; Yang JC; Schrump DS; Rosenberg SA; Sherry RM
Ann Surg Oncol; 2017 Jan; 24(1):135-141. PubMed ID: 27638681
[TBL] [Abstract][Full Text] [Related]
7. Surgical Resection of Pulmonary Metastases from Melanoma in Oligometastatic Patients: Results from a Multicentric Study in the Era of Immunoncology and Targeted Therapy.
Meacci E; Nachira D; Congedo MT; Ibrahim M; Pariscenti G; Petrella F; Casiraghi M; De Stefani A; Del Regno L; Peris K; Triumbari EKA; Schinzari G; Rossi E; Petracca-Ciavarella L; Vita ML; Chiappetta M; Siciliani A; Peritore V; Manitto M; Morelli L; Zanfrini E; Tabacco D; Calabrese G; Bardoni C; Evangelista J; Spaggiari L; Margaritora S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173927
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
Pham JP; Joshua AM; da Silva IP; Dummer R; Goldinger SM
Curr Oncol Rep; 2023 Jun; 25(6):609-621. PubMed ID: 36988735
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Patel SP; Othus M; Chen Y; Wright GP; Yost KJ; Hyngstrom JR; Hu-Lieskovan S; Lao CD; Fecher LA; Truong TG; Eisenstein JL; Chandra S; Sosman JA; Kendra KL; Wu RC; Devoe CE; Deutsch GB; Hegde A; Khalil M; Mangla A; Reese AM; Ross MI; Poklepovic AS; Phan GQ; Onitilo AA; Yasar DG; Powers BC; Doolittle GC; In GK; Kokot N; Gibney GT; Atkins MB; Shaheen M; Warneke JA; Ikeguchi A; Najera JE; Chmielowski B; Crompton JG; Floyd JD; Hsueh E; Margolin KA; Chow WA; Grossmann KF; Dietrich E; Prieto VG; Lowe MC; Buchbinder EI; Kirkwood JM; Korde L; Moon J; Sharon E; Sondak VK; Ribas A
N Engl J Med; 2023 Mar; 388(9):813-823. PubMed ID: 36856617
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Outcomes With Nivolumab in Patients With Wild-Type
Robert C; Long GV; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Rutkowski P; Hassel JC; McNeil CM; Kalinka EA; Lebbé C; Charles J; Hernberg MM; Savage KJ; Chiarion-Sileni V; Mihalcioiu C; Mauch C; Arance A; Cognetti F; Ny L; Schmidt H; Schadendorf D; Gogas H; Zoco J; Re S; Ascierto PA; Atkinson V
J Clin Oncol; 2020 Nov; 38(33):3937-3946. PubMed ID: 32997575
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Hauschild A; Ascierto PA; Schadendorf D; Grob JJ; Ribas A; Kiecker F; Dutriaux C; Demidov LV; Lebbé C; Rutkowski P; Blank CU; Gutzmer R; Millward M; Kefford R; Haas T; D'Amelio A; Gasal E; Mookerjee B; Chapman PB
Eur J Cancer; 2020 Jan; 125():114-120. PubMed ID: 31864178
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Robert C; Flaherty K; Nathan P; Hersey P; Garbe C; Milhem M; Demidov L; Mohr P; Hassel JC; Rutkowski P; Dummer R; Utikal J; Kiecker F; Larkin J; D'Amelio A; Mookerjee B; Schadendorf D
Eur J Cancer; 2019 Mar; 109():61-69. PubMed ID: 30690294
[TBL] [Abstract][Full Text] [Related]
14. Melanoma treatment in review.
Domingues B; Lopes JM; Soares P; Pópulo H
Immunotargets Ther; 2018; 7():35-49. PubMed ID: 29922629
[TBL] [Abstract][Full Text] [Related]
15. Emergency surgery for metastatic melanoma.
Mantas D; Tsaparas P; Charalampoudis P; Gogas H; Kouraklis G
Int J Surg Oncol; 2014; 2014():987170. PubMed ID: 25530876
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
